A phase II study of pembrolizumab and mogamulizumab in advanced-stage, relapsed/refractory cutaneous T-cell lymphomas

Status: Open to Accrual
Read More

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Status: Open to Accrual
Read More

A Single Arm Phase II Study with Safety Run-in of Peptide Receptor Radionuclide Therapy (PRRT) in Combination with Immunotherapy for Patients with Merkel Cell Cancer (iPRRT Study)

Status: Open to Accrual 
Read More

A Phase II Trial of Avelumab or Hydroxychloroquine with or without Palbociclib to Eliminate Dormant Breast Cancer (“PALAVY”)

Status: Open to Accrual
Read More

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Status: Open to Accrual
Read More

A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024

Status: Open to Accrual
Read More

A Phase II Study of Peri-Operative NovoTTF-200T(P) in Combination with Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI21-500

Status: Open to Accrual
Read More

Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: BTCRC-HEM15-027

Status: Open to Accrual
Read More

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Status: Open to Accrual
Read More

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm

Status: Open to Accrual
Read More

A Randomized, Multi-Cohort Phase II Trial of Temozolomide and Atezolizumab
as Second Line Treatment for Small Cell Lung Cancer

Status: Open to Accrual
Read More

A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Status: Open to Accrual
Read More

A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma

Status: Closed to Accrual
Read More

A Phase II Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Resectable Hepatic-Limited Metastatic Colorectal Cancer HCRN: GI16-288

Status: Closed to Accrual
Read More

A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y-90 TARE in Patients with Unresectable Hepatocellular Carcinoma (HCC)

Status: Closed to Accrual
Read More

Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188

Status: Closed to Accrual
Read More

Neoadjuvant gemcitabine, cisplatin, plus nivolumab in patients with muscle-invasive bladder cancer with selective bladder sparing

Status: Closed to Accrual
Read More

Phase II study of front line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced renal cell carcinoma

Status: Closed to Accrual
Read More

Randomized phase 2 trial of gemcitabine + carboplatin + nivolumab versus gemcitabine + oxaliplatin + nivolumab in cisplatin-ineligible patients with metastatic urothelial cancer

Status: Closed to Accrual
Read More

Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade

Status: Closed to Accrual
Read More